1. Ireland Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Medtronic plc

Medtronic plc

MDT
Medtronic plcUS flagNew York Stock Exchange
91.27
USD
+0.69
- -
116.83BMarket Cap
Medtronic plc
MDT
(New York Stock Exchange)

Recent

price

91.27

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
14.39
15.36
16.28
16.97
18.49
20.45
21.55
22.08
22.7
21.57
22.39
23.6
23.48
24.38
26.09
- -
28.37
Revenue per Share
2.87
3.43
3.4
3.06
2.44
2.51
2.92
2.29
3.44
3.57
2.68
3.75
2.83
2.77
3.63
- -
3.75
Basic EPS, GAAP
2.96
3.77
4.4
4.55
3.95
2.96
4.08
2.67
4.36
4.49
3.63
4.45
3.44
3.92
4.03
- -
4.23
Free Cash Flow per Basic Share
0.9
0.97
1.04
1.11
1.22
1.52
1.72
1.84
2
2.16
2.32
2.52
2.72
2.76
2.79
- -
2.84
Dividend per Share
14.92
16.5
18.38
19.46
37.44
37.21
36.66
37.45
37.36
37.83
38.23
39.49
38.69
38.29
37.46
38.64
38.64
Book Value per Share
3.48
4.37
5.58
6.57
-10.83
-11.68
-8.55
-7.79
-7.78
-6.09
-6.15
-2.66
-3.6
-3.05
-4.2
-2.55
-2.55
Tangible Book Value per Share
1,077
1,054
1,019
1,002
1,096
1,410
1,379
1,357
1,346
1,341
1,345
1,342
1,330
1,328
1,286
- -
1,282
Basic Weighted Avg Shares
15,508
16,184
16,590
17,005
20,261
28,833
29,710
29,953
30,557
28,913
30,117
31,686
31,227
32,364
33,537
36,364
36,363
Sales/Revenue/Turnover
28.76
27.7
28.75
28.33
22.49
20.67
20.15
20.14
21.7
18.06
16.25
18.65
18.67
17.06
19.5
18.78
18.77
Operating Margin (%)
804
833
819
850
1,306
2,820
2,917
2,644
2,659
2,663
2,702
2,707
2,697
2,647
2,861
2,958
2,958
Depreciation Expense
3,096
3,617
3,467
3,065
2,675
3,538
4,028
3,104
4,631
4,789
3,606
5,039
3,758
3,676
4,662
4,801
4,801
Net Income, GAAP
16.62
17.61
18.44
17.27
23.26
18.4
12.56
45.46
10.53
- -
6.8
8.27
29.46
23.42
16.63
21.17
21.17
Effective Tax Rate (%)
19.96
22.35
20.9
18.02
13.2
12.27
13.56
10.36
15.16
16.56
11.97
15.9
12.03
11.36
13.9
13.2
13.2
Profit Margin (%)
4,424
10,409
13,902
15,651
21,671
16,435
10,609
12,896
13,495
11,665
14,039
10,665
12,624
11,146
10,935
13,129
13,129
Working Capital
7,934
7,192
9,691
10,259
33,673
30,020
25,881
23,705
24,477
22,021
26,378
20,372
24,344
23,932
25,642
26,173
26,173
LT Debt
15,968
17,113
18,671
19,443
53,230
52,063
50,330
50,822
50,212
50,872
51,602
52,722
51,665
50,420
48,256
50,072
50,072
Total Equity
14.88
13.88
13.67
13.14
5.75
5.6
6.24
4.07
7.74
- -
5.92
6.97
5.34
5.51
7.06
6.87
6.87
Return on Invested Capital (%)
13.95
14.68
13.31
11.15
5.28
5.42
5.98
4.66
7.76
- -
5.78
7.14
5.47
5.54
6.89
6.88
6.88
Return on Capital (%)
20.24
21.87
19.38
16.08
7.36
6.72
7.88
6.15
9.19
9.5
7.06
9.69
7.22
7.23
9.49
9.85
9.85
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
ST Debt
1,420
191
1,788
LT Borrowings
27,625
27,822
26,119
LT Finance Leases
55
58
54
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,282
1,283
1,280
Market Capitalization
116,276
132,135
103,656

Working Capital

FRC

•

in mil. unless spec.
Oct'26
Jan'26
Apr'26
Total Current Assets
23,996
24,071
24,787
Cash, Cash Equivalents & STI
8,327
8,383
9,220
Accounts Receivable, Net
6,389
6,359
6,643
Inventories
6,156
6,309
5,951
Total Current Liabilities
9,935
9,495
11,658
Payables & Accruals
6,384
6,723
7,192
ST Debt
1,420
191
1,788
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.36%
-0.55%
3.76%
Free Cash Flow
6.21%
3.38%
4.65%
Net Income, GAAP
6.07%
8.39%
2.98%
Sales/Revenue/Turnover
2.41%
3.89%
8.43%
Total Cash Common Dividend
5.53%
3.2%
1.39%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
7,702
7,984
8,089
8,589
32,364
2025
7,915
8,403
8,292
8,927
33,537
2026
8,578
8,961
9,017
9,807
36,364

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.59
0.68
0.99
0.49
2.77
2025
0.81
0.99
1.01
0.82
3.63
2026
0.81
1.07
0.89
0.97
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.69
0.69
0.69
0.69
2.76
2025
0.69
0.7
0.7
0.7
2.79
2026
0.71
0.71
0.71
0.71
- -
Similar Companies
Nova Eye Medical Limited (EYE.AX)
Envoy Medical, Inc. (COCH)
Shenzhen Edge Medical Co Ltd (2675.HK)
Family Office of America Inc. (FOFA)
Lumos Diagnostics Holdings Ltd. (LDXHF)
Dignitana AB (publ) (DIZTF)
Business
Medtronic plc (NYSE: MDT) develops, manufactures, and markets a wide range of medical devices and therapies for the treatment of chronic diseases worldwide. The company offers products across four main segments: cardiovascular (including pacemakers, defibrillators, heart valves, and coronary stents under brands such as Evera, Protecta, and CoreValve); medical surgical (featuring surgical navigation systems, endoscopic tools, and stapling devices like Hugo RAS and Valiant NaviCore); neuroscience (encompassing spinal cord stimulators, deep brain stimulation systems, and intrathecal drug delivery pumps such as Incepta and SynchroMed II); and diabetes (primarily continuous glucose monitoring systems, insulin pumps, and related software through the MiniMed and Guardian brands). Medtronic provides services including patient management software, remote monitoring platforms, and clinical decision support tools to healthcare providers, hospitals, clinics, and patients globally. Founded in 1949 and headquartered in Dublin, Ireland, with principal executive offices in Minneapolis, Minnesota, USA, Medtronic operates in more than 150 countries, serving markets in North America, Europe, Asia-Pacific, Latin America, and the Middle East through direct sales forces, distributors, and subsidiaries. The company targets physicians, hospitals, ambulatory surgery centers, and home care settings, with a focus on minimally invasive therapies and digital health solutions. Key subsidiaries include Covidien (acquired in 2015 for surgical and patient monitoring products) and Intersect ENT (recently integrated for sinus implants). In the past 1-2 years, Medtronic has pursued strategic expansions including the FDA approval and U.S. launch of the Hugo robotic-assisted surgery (RAS) system in 2024 for soft tissue indications, building on its European CE Mark; a multi-year collaboration with NVIDIA announced in 2024 to advance AI-enabled therapies using Medtronic's Gigamon data platform; and the acquisition of Mazor Robotics in 2018 followed by ongoing enhancements to its spinal robotics portfolio with the Mazor X Stealth Edition. The company completed a $4.1 billion acquisition of Covidien assets integration and reported expansions in diabetes care via the Simplera Sync sensor FDA clearance in 2024. Medtronic also announced organizational realignments in 2025 to streamline its four operating units amid portfolio optimization efforts.

Company News

APIChatGPT

  • defenseworld.net

    Baldwin Investment Management LLC Makes New Investment in Medtronic PLC $MDT

  • defenseworld.net

    Atria Investments Inc Has $12.24 Million Position in Medtronic PLC $MDT

  • defenseworld.net

    Asset Management One Co. Ltd. Cuts Stock Holdings in Medtronic PLC $MDT

  • zacks.com

    Wall Street Bulls Look Optimistic About Medtronic (MDT): Should You Buy?

  • defenseworld.net

    Ballast Inc. Acquires 7,320 Shares of Medtronic PLC $MDT

  • defenseworld.net

    24,967 Shares in Medtronic PLC $MDT Acquired by First Bank & Trust

  • zacks.com

    Medtronic (MDT) Increases Despite Market Slip: Here's What You Need to Know

  • seekingalpha.com

    Medtronic: Buy This Undervalued Dividend Aristocrat Before The Market Catches On

  • 247wallst.com

    We Said These 4 Dividend Aristocrats Could Soar. Here's How They Did, Plus 3 New Picks.

  • fool.com

    Medtronic vs. Intuitive Surgical: Which MedTech Stock Is the Better Buy Right Now?

  • etftrends.com

    I've Got Royalty on the Brain

  • defenseworld.net

    180 Wealth Advisors LLC Lowers Holdings in Medtronic PLC $MDT

  • prnewswire.com

    Medtronic announces expanded CE Mark indication for Affera™ Mapping and Ablation System and Sphere-9™ Catheter for treatment of ventricular arrhythmias

  • fool.com

    I'm Calling It: Medtronic (MDT) Will Soar 40% by the End of 2026

  • fool.com

    Retirees: 3 High-Yielding Dividend Stocks to Buy for Long-Term Stability and Recurring Cash Flow

  • zacks.com

    Medtronic (MDT) Laps the Stock Market: Here's Why

  • defenseworld.net

    Avidity Partners Management LP Sells 7,600 Shares of Medtronic PLC $MDT

  • zacks.com

    Medtronic PLC (MDT) Is a Trending Stock: Facts to Know Before Betting on It

  • fool.com

    This Stock Is Knocking on the Door of the Dividend Kings -- and Wall Street Thinks It Has Room to Run

  • zacks.com

    Medtronic (MDT) Outpaces Stock Market Gains: What You Should Know